A Study Comparing BL-B01D1 in Combination With Osimertinib Versus Osimertinib Alone in Patients With Locally Advanced, Unresectable EGFR-mutated Non-small Cell Lung Cancer(Stage III) Whose Disease Has Not Progressed Following Definitive Platinum-based Chemoradiation Therapy(PANKU-Lung08)
Clinical trial NCT07640789 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07640789
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2026-06-01
- Primary completion
- 2030-12-01
- Enrollment
- 418
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.